<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">34122374</PMID><DateRevised><Year>2021</Year><Month>06</Month><Day>15</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1664-302X</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><PubDate><Year>2021</Year></PubDate></JournalIssue><Title>Frontiers in microbiology</Title><ISOAbbreviation>Front Microbiol</ISOAbbreviation></Journal><ArticleTitle>Neonatal Murine Model of Coxsackievirus A2 Infection for the Evaluation of Antiviral Therapeutics and Vaccination.</ArticleTitle><Pagination><StartPage>658093</StartPage><MedlinePgn>658093</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">658093</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fmicb.2021.658093</ELocationID><Abstract><AbstractText>Coxsackievirus (CV) A2 has emerged as an important etiological agent in the pathogen spectrum of hand, foot, and mouth disease (HFMD). The symptoms of CVA2 infections are generally mild, but worsen rapidly in some people, posing a serious threat to children's health. However, compared with enterovirus 71 detected frequently in fatal cases, limited attention has been paid to CVA2 infections because of its benign clinical course. In the present study, we identified three CVA2 strains from HFMD infections and used the cell-adapted CVA2 strain HN202009 to inoculate 5-day-old BALB/c mice intramuscularly. These mice developed remarkably neurological symptoms such as ataxia, hind-limb paralysis, and death. Histopathological determination showed neuronophagia, pulmonary hemorrhage, myofiberlysis and viral myocarditis. Viral replication was detected in multiple organs and tissues, and CVA2 exhibited strong tropism to muscle tissue. The severity of illness was associated with abnormally high levels of inflammatory cytokines, including interleukin (IL)-6, IL-10, tumor necrosis factor &#x3b1;, and monocyte chemotactic protein 1, although the blockade of these proinflammatory cytokines had no obvious protection. We also tested whether an experimental formaldehyde-inactivated CVA2 vaccine could induce protective immune response in adult mice. The CVA2 antisera from the vaccinated mice were effective against CVA2 infection. Moreover, the inactivated CVA2 vaccine could successfully generate immune protection in neonatal mice. Our results indicated that the neonatal mouse model could be a useful tool to study CVA2 infection and to develop CVA2 vaccines.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 Ji, Qin, Tao, Zhu, Liang, Zhou, Chen, Zhang, Yang, Duan and Jin.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ji</LastName><ForeName>Wangquan</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, College of Public Health, Zhengzhou University, Zhengzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qin</LastName><ForeName>Luwei</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Henan Province Center for Disease Control and Prevention, Zhengzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tao</LastName><ForeName>Ling</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>School of Public Health, Xinxiang Medical University, Xinxiang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Peiyu</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, College of Public Health, Zhengzhou University, Zhengzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Ruonan</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, College of Public Health, Zhengzhou University, Zhengzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Guangyuan</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>School of Public Health, Xinxiang Medical University, Xinxiang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Shuaiyin</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, College of Public Health, Zhengzhou University, Zhengzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Weiguo</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Immunology, Duke University Medical Center, Durham, NC, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Haiyan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, College of Public Health, Zhengzhou University, Zhengzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duan</LastName><ForeName>Guangcai</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, College of Public Health, Zhengzhou University, Zhengzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>Yuefei</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, College of Public Health, Zhengzhou University, Zhengzhou, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>05</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Microbiol</MedlineTA><NlmUniqueID>101548977</NlmUniqueID><ISSNLinking>1664-302X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">antiviral</Keyword><Keyword MajorTopicYN="N">coxsackievirus A2</Keyword><Keyword MajorTopicYN="N">foot</Keyword><Keyword MajorTopicYN="N">hand</Keyword><Keyword MajorTopicYN="N">mouth disease</Keyword><Keyword MajorTopicYN="N">murine model</Keyword><Keyword MajorTopicYN="N">vaccine</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>1</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>4</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>6</Month><Day>14</Day><Hour>9</Hour><Minute>36</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>6</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>15</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>5</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34122374</ArticleId><ArticleId IdType="pmc">PMC8192712</ArticleId><ArticleId IdType="doi">10.3389/fmicb.2021.658093</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Baek K., Yeo S., Lee B., Park K., Song J., Yu J., et al. (2011). Epidemics of enterovirus infection in Chungnam Korea, 2008 and 2009. Virol. J. 8:297. 10.1186/1743-422X-8-297</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-8-297</ArticleId><ArticleId IdType="pmc">PMC3130694</ArticleId><ArticleId IdType="pubmed">21668960</ArticleId></ArticleIdList></Reference><Reference><Citation>Bendig J. W., O&#x2019;Brien P. S., Muir P., Porter H. J., Caul E. O. (2001). Enterovirus sequences resembling coxsackievirus A2 detected in stool and spleen from a girl with fatal myocarditis. J. Med. Virol. 64 482&#x2013;486.</Citation><ArticleIdList><ArticleId IdType="pubmed">11468733</ArticleId></ArticleIdList></Reference><Reference><Citation>Bianconi V., Sahebkar A., Atkin S. L., Pirro M. (2018). The regulation and importance of monocyte chemoattractant protein-1. Curr. Opin. Hematol. 25 44&#x2013;51. 10.1097/MOH.0000000000000389</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MOH.0000000000000389</ArticleId><ArticleId IdType="pubmed">28914666</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai Y., Liu Q., Huang X., Li D., Ku Z., Zhang Y., et al. (2013). Active immunization with a Coxsackievirus A16 experimental inactivated vaccine induces neutralizing antibodies and protects mice against lethal infection. Vaccine 31 2215&#x2013;2221. 10.1016/j.vaccine.2013.03.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2013.03.007</ArticleId><ArticleId IdType="pubmed">23499596</ArticleId></ArticleIdList></Reference><Reference><Citation>Chansaenroj J., Auphimai C., Puenpa J., Mauleekoonphairoj J., Wanlapakorn N., Vuthitanachot V., et al. (2017). High prevalence of coxsackievirus A2 in children with herpangina in Thailand in 2015. Virusdisease 28 111&#x2013;114. 10.1007/s13337-017-0366-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13337-017-0366-8</ArticleId><ArticleId IdType="pmc">PMC5377860</ArticleId><ArticleId IdType="pubmed">28466062</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen K. T., Chang H. L., Wang S. T., Cheng Y. T., Yang J. Y. (2007). Epidemiologic features of hand-foot-mouth disease and herpangina caused by enterovirus 71 in Taiwan, 1998-2005. Pediatrics 120 e244&#x2013;e252. 10.1542/peds.2006-3331</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2006-3331</ArticleId><ArticleId IdType="pubmed">17671037</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S. P., Huang Y. C., Li W. C., Chiu C. H., Huang C. G., Tsao K. C., et al. (2010). Comparison of clinical features between coxsackievirus A2 and enterovirus 71 during the enterovirus outbreak in Taiwan, 2008: a children&#x2019;s hospital experience. J. Microbiol. Immunol. Infect. 43 99&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pubmed">20457425</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong C., Liu L., Zhao H., Wang J., Liao Y., Zhang X., et al. (2011). Immunoprotection elicited by an enterovirus type 71 experimental inactivated vaccine in mice and rhesus monkeys. Vaccine 29 6269&#x2013;6275. 10.1016/j.vaccine.2011.06.044</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.06.044</ArticleId><ArticleId IdType="pubmed">21722686</ArticleId></ArticleIdList></Reference><Reference><Citation>Franca C. N., Izar M. C. O., Hortencio M. N. S., do Amaral J. B., Ferreira C. E. S., Tuleta I. D., et al. (2017). Monocyte subtypes and the CCR2 chemokine receptor in cardiovascular disease. Clin. Sci. (Lond) 131 1215&#x2013;1224.</Citation><ArticleIdList><ArticleId IdType="pubmed">28566450</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu C., Lu L., Wu H., Shaman J., Cao Y., Fang F., et al. (2016). Placental antibody transfer efficiency and maternal levels: specific for measles, coxsackievirus A16, enterovirus 71, poliomyelitis I-III and HIV-1 antibodies. Sci. Rep. 6:38874. 10.1038/srep38874</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep38874</ArticleId><ArticleId IdType="pmc">PMC5146964</ArticleId><ArticleId IdType="pubmed">27934956</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujii K., Nagata N., Sato Y., Ong K. C., Wong K. T., Yamayoshi S., et al. (2013). Transgenic mouse model for the study of enterovirus 71 neuropathogenesis. Proc. Natl. Acad. Sci. U.S.A. 110 14753&#x2013;14758. 10.1073/pnas.1217563110</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1217563110</ArticleId><ArticleId IdType="pmc">PMC3767555</ArticleId><ArticleId IdType="pubmed">23959904</ArticleId></ArticleIdList></Reference><Reference><Citation>Georgakis M. K., Malik R., Bjorkbacka H., Pana T. A., Demissie S., Ayers C., et al. (2019). Circulating monocyte chemoattractant protein-1 and risk of stroke: meta-analysis of population-based studies involving 17 180 individuals. Circ. Res. 125 773&#x2013;782.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6763364</ArticleId><ArticleId IdType="pubmed">31476962</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y. F., Yang F., Du J., Dong J., Zhang T., Wu Z. Q., et al. (2011). Complete genome analysis of coxsackievirus A2, A4, A5, and A10 strains isolated from hand, foot, and mouth disease patients in China revealing frequent recombination of human enterovirus A. J. Clin. Microbiol. 49 2426&#x2013;2434. 10.1128/JCM.00007-11</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.00007-11</ArticleId><ArticleId IdType="pmc">PMC3147834</ArticleId><ArticleId IdType="pubmed">21543560</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang J., Liao Q., Ooi M. H., Cowling B. J., Chang Z., Wu P., et al. (2018). Epidemiology of recurrent hand, foot and mouth disease, China, 2008-2015. Emerg. Infect. Dis. 24 432&#x2013;442.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5823341</ArticleId><ArticleId IdType="pubmed">29460747</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunter C. A., Jones S. A. (2015). IL-6 as a keystone cytokine in health and disease. Nat. Immunol. 16 448&#x2013;457. 10.1038/ni.3153</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.3153</ArticleId><ArticleId IdType="pubmed">25898198</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalliolias G. D., Ivashkiv L. B. (2016). TNF biology, pathogenic mechanisms and emerging therapeutic strategies. Nat. Rev. Rheumatol. 12 49&#x2013;62. 10.1038/nrrheum.2015.169</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrrheum.2015.169</ArticleId><ArticleId IdType="pmc">PMC4809675</ArticleId><ArticleId IdType="pubmed">26656660</ArticleId></ArticleIdList></Reference><Reference><Citation>Khong W. X., Foo D. G., Trasti S. L., Tan E. L., Alonso S. (2011). Sustained high levels of interleukin-6 contribute to the pathogenesis of enterovirus 71 in a neonate mouse model. J. Virol. 85 3067&#x2013;3076. 10.1128/JVI.01779-10</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01779-10</ArticleId><ArticleId IdType="pmc">PMC3067852</ArticleId><ArticleId IdType="pubmed">21228224</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohlmeier J. E., Woodland D. L. (2009). Immunity to respiratory viruses. Annu. Rev. Immunol. 27 61&#x2013;82. 10.1146/annurev.immunol.021908.132625</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.immunol.021908.132625</ArticleId><ArticleId IdType="pubmed">18954284</ArticleId></ArticleIdList></Reference><Reference><Citation>Lefkowitz E. J., Dempsey D. M., Hendrickson R. C., Orton R. J., Siddell S. G., Smith D. B. (2018). Virus taxonomy: the database of the International Committee on Taxonomy of Viruses (ICTV). Nucleic Acids Res. 46 D708&#x2013;D717. 10.1093/nar/gkx932</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkx932</ArticleId><ArticleId IdType="pmc">PMC5753373</ArticleId><ArticleId IdType="pubmed">29040670</ArticleId></ArticleIdList></Reference><Reference><Citation>Li R., Liu L., Mo Z., Wang X., Xia J., Liang Z., et al. (2014). An inactivated enterovirus 71 vaccine in healthy children. N. Engl. J. Med. 370 829&#x2013;837.</Citation><ArticleIdList><ArticleId IdType="pubmed">24571755</ArticleId></ArticleIdList></Reference><Reference><Citation>Liou A. T., Wu S. Y., Liao C. C., Chang Y. S., Chang C. S., Shih C. (2016). A new animal model containing human SCARB2 and lacking stat-1 is highly susceptible to EV71. Sci. Rep. 6:31151. 10.1038/srep31151</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep31151</ArticleId><ArticleId IdType="pmc">PMC4976353</ArticleId><ArticleId IdType="pubmed">27499235</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q., Shi J., Huang X., Liu F., Cai Y., Lan K., et al. (2014). A murine model of coxsackievirus A16 infection for anti-viral evaluation. Antiviral Res. 105 26&#x2013;31. 10.1016/j.antiviral.2014.02.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2014.02.015</ArticleId><ArticleId IdType="pubmed">24583030</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao Q. Y., Liao X. Y., Yu X., Li N., Zhu F. C., Zeng Y., et al. (2010). Dynamic change of mother-source neutralizing antibodies against enterovirus 71 and coxsackievirus A16 in infants. Chin. Med. J. (Engl.) 123 1679&#x2013;1684.</Citation><ArticleIdList><ArticleId IdType="pubmed">20819628</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao Q., Wang Y., Gao R., Shao J., Yao X., Lang S., et al. (2012). A neonatal mouse model of coxsackievirus A16 for vaccine evaluation. J. Virol. 86 11967&#x2013;11976. 10.1128/JVI.00902-12</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00902-12</ArticleId><ArticleId IdType="pmc">PMC3486452</ArticleId><ArticleId IdType="pubmed">22951825</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao Q., Wang Y., Yao X., Bian L., Wu X., Xu M., et al. (2014). Coxsackievirus A16: epidemiology, diagnosis, and vaccine. Hum. Vaccin. Immunother. 10 360&#x2013;367. 10.4161/hv.27087</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/hv.27087</ArticleId><ArticleId IdType="pmc">PMC4185891</ArticleId><ArticleId IdType="pubmed">24231751</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin J., Crossland G., Wood D. J., Minor P. D. (2003). Characterization of formaldehyde-inactivated poliovirus preparations made from live-attenuated strains. J. Gen. Virol. 84(Pt 7) 1781&#x2013;1788. 10.1099/vir.0.19088-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.19088-0</ArticleId><ArticleId IdType="pubmed">12810872</ArticleId></ArticleIdList></Reference><Reference><Citation>Mihara M., Hashizume M., Yoshida H., Suzuki M., Shiina M. (2012). IL-6/IL-6 receptor system and its role in physiological and pathological conditions. Clin. Sci. (Lond.) 122 143&#x2013;159. 10.1042/CS20110340</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/CS20110340</ArticleId><ArticleId IdType="pubmed">22029668</ArticleId></ArticleIdList></Reference><Reference><Citation>Molet L., Saloum K., Marque-Juillet S., Garbarg-Chenon A., Henquell C., Schuffenecker I., et al. (2016). Enterovirus infections in hospitals of Ile de France region over 2013. J. Clin. Virol. 74 37&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">26655266</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrison B. E., Park S. J., Mooney J. M., Mehrad B. (2003). Chemokine-mediated recruitment of NK cells is a critical host defense mechanism in invasive aspergillosis. J. Clin. Invest. 112 1862&#x2013;1870. 10.1172/JCI18125</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI18125</ArticleId><ArticleId IdType="pmc">PMC296992</ArticleId><ArticleId IdType="pubmed">14679181</ArticleId></ArticleIdList></Reference><Reference><Citation>Oberste M. S., Penaranda S., Maher K., Pallansch M. A. (2004). Complete genome sequences of all members of the species Human enterovirus A. J. Gen. Virol. 85(Pt 6) 1597&#x2013;1607. 10.1099/vir.0.79789-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.79789-0</ArticleId><ArticleId IdType="pubmed">15166444</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohara N., Kaneko M., Nishibori T., Sato K., Furukawa T., Koike T., et al. (2016). Fulminant Type 1 diabetes mellitus associated with coxsackie virus type A2 infection: a case report and literature review. Intern. Med. 55 643&#x2013;646. 10.2169/internalmedicine.55.5292</Citation><ArticleIdList><ArticleId IdType="doi">10.2169/internalmedicine.55.5292</ArticleId><ArticleId IdType="pubmed">26984083</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong K. C., Devi S., Cardosa M. J., Wong K. T. (2010). Formaldehyde-inactivated whole-virus vaccine protects a murine model of enterovirus 71 encephalomyelitis against disease. J. Virol. 84 661&#x2013;665.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2798416</ArticleId><ArticleId IdType="pubmed">19864378</ArticleId></ArticleIdList></Reference><Reference><Citation>Ooi M. H., Wong S. C., Lewthwaite P., Cardosa M. J., Solomon T. (2010). Clinical features, diagnosis, and management of enterovirus 71. Lancet Neurol. 9 1097&#x2013;1105. 10.1016/S1474-4422(10)70209-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(10)70209-X</ArticleId><ArticleId IdType="pubmed">20965438</ArticleId></ArticleIdList></Reference><Reference><Citation>Park K., Lee B., Baek K., Cheon D., Yeo S., Park J., et al. (2012). Enteroviruses isolated from herpangina and hand-foot-and-mouth disease in Korean children. Virol. J. 9:205. 10.1186/1743-422X-9-205</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-9-205</ArticleId><ArticleId IdType="pmc">PMC3490919</ArticleId><ArticleId IdType="pubmed">22985487</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed L. J. M. H. (1938). A simple method of estimating 50 percent end-points. Am. J. Epidemiol. 27 493&#x2013;497.</Citation></Reference><Reference><Citation>Scanga C. A., Mohan V. P., Joseph H., Yu K., Chan J., Flynn J. L. (1999). Reactivation of latent tuberculosis: variations on the Cornell murine model. Infect. Immun. 67 4531&#x2013;4538. 10.1128/IAI.67.9.4531-4538.1999</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/IAI.67.9.4531-4538.1999</ArticleId><ArticleId IdType="pmc">PMC96774</ArticleId><ArticleId IdType="pubmed">10456896</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon T., Lewthwaite P., Perera D., Cardosa M. J., McMinn P., Ooi M. H. (2010). Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect. Dis. 10 778&#x2013;790. 10.1016/S1473-3099(10)70194-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(10)70194-8</ArticleId><ArticleId IdType="pubmed">20961813</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka T., Narazaki M., Kishimoto T. (2014). IL-6 in inflammation, immunity, and disease. Cold Spring Harb. Perspect. Biol. 6:a016295. 10.1101/cshperspect.a016295</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a016295</ArticleId><ArticleId IdType="pmc">PMC4176007</ArticleId><ArticleId IdType="pubmed">25190079</ArticleId></ArticleIdList></Reference><Reference><Citation>Udalova I., Monaco C., Nanchahal J., Feldmann M. (2016). Anti-TNF Therapy. Microbiol. Spectr. 4 1&#x2013;11. 10.1128/microbiolspec.MCHD-0022-2015</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/microbiolspec.MCHD-0022-2015</ArticleId><ArticleId IdType="pubmed">27726761</ArticleId></ArticleIdList></Reference><Reference><Citation>Via C. S., Shustov A., Rus V., Lang T., Nguyen P., Finkelman F. D. (2001). In vivo neutralization of TNF-alpha promotes humoral autoimmunity by preventing the induction of CTL. J. Immunol. 167 6821&#x2013;6826. 10.4049/jimmunol.167.12.6821</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.167.12.6821</ArticleId><ArticleId IdType="pubmed">11739498</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S. M., Lei H. Y., Huang M. C., Su L. Y., Lin H. C., Yu C. K., et al. (2006). Modulation of cytokine production by intravenous immunoglobulin in patients with enterovirus 71-associated brainstem encephalitis. J. Clin. Virol. 37 47&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">16861032</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y. F., Yu C. K. (2014). Animal models of enterovirus 71 infection: applications and limitations. J. Biomed. Sci. 21:31. 10.1186/1423-0127-21-31</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1423-0127-21-31</ArticleId><ArticleId IdType="pmc">PMC4013435</ArticleId><ArticleId IdType="pubmed">24742252</ArticleId></ArticleIdList></Reference><Reference><Citation>Xing W., Liao Q., Viboud C., Zhang J., Sun J., Wu J. T., et al. (2014). Hand, foot, and mouth disease in China, 2008-12: an epidemiological study. Lancet Infect. Dis. 14 308&#x2013;318. 10.1016/S1473-3099(13)70342-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(13)70342-6</ArticleId><ArticleId IdType="pmc">PMC4035015</ArticleId><ArticleId IdType="pubmed">24485991</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang L., Mao Q., Li S., Gao F., Zhao H., Liu Y., et al. (2016). A neonatal mouse model for the evaluation of antibodies and vaccines against coxsackievirus A6. Antiviral Res. 134 50&#x2013;57. 10.1016/j.antiviral.2016.08.025</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2016.08.025</ArticleId><ArticleId IdType="pubmed">27582066</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Q., Gu X., Zhang Y., Wei H., Li Q., Fan H., et al. (2018). Persistent circulation of genotype D coxsackievirus A2 in mainland of China since 2008. PLoS One 13:e0204359. 10.1371/journal.pone.0204359</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0204359</ArticleId><ArticleId IdType="pmc">PMC6147602</ArticleId><ArticleId IdType="pubmed">30235342</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang T., Xie T., Li H., Song X., Yue L., Wang X., et al. (2020). Immune responses of a CV-A16 live attenuated candidate strain and its protective effects in rhesus monkeys. Emerg. Microbes Infect. 9 2136&#x2013;2146. 10.1080/22221751.2020.1823889</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2020.1823889</ArticleId><ArticleId IdType="pmc">PMC7580583</ArticleId><ArticleId IdType="pubmed">32930072</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao P. P., Miao Z. P., Xu F., Lu H. J., Sun Y. S., Xia Y., et al. (2019). An adult gerbil model for evaluating potential coxsackievirus A16 vaccine candidates. Vaccine 37 5341&#x2013;5349. 10.1016/j.vaccine.2019.07.046</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2019.07.046</ArticleId><ArticleId IdType="pubmed">31351798</ArticleId></ArticleIdList></Reference><Reference><Citation>Yen T. Y., Huang Y. P., Hsu Y. L., Chang Y. T., Lin H. C., Wu H. S., et al. (2017). A case of recombinant coxsackievirus A2 infection with neurological complications in Taiwan. J. Microbiol. Immunol. Infect. 50 928&#x2013;930. 10.1016/j.jmii.2016.08.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmii.2016.08.012</ArticleId><ArticleId IdType="pubmed">28082064</ArticleId></ArticleIdList></Reference><Reference><Citation>Yip C. C., Lau S. K., Woo P. C., Wong S. S., Tsang T. H., Lo J. Y., et al. (2013). Recombinant coxsackievirus A2 and deaths of children, Hong Kong, 2012. Emerg. Infect. Dis. 19 1285&#x2013;1288. 10.3201/eid1908.121498</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid1908.121498</ArticleId><ArticleId IdType="pmc">PMC3739500</ArticleId><ArticleId IdType="pubmed">23876841</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z., Dong Z., Li J., Carr M. J., Zhuang D., Wang J., et al. (2017a). Protective efficacies of formaldehyde-inactivated whole-virus vaccine and antivirals in a murine model of coxsackievirus A10 infection. J Virol 91:e00333-17. 10.1128/JVI.00333-17</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00333-17</ArticleId><ArticleId IdType="pmc">PMC5469256</ArticleId><ArticleId IdType="pubmed">28424287</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z., Dong Z., Wang Q., Carr M. J., Li J., Liu T., et al. (2018). Characterization of an inactivated whole-virus bivalent vaccine that induces balanced protective immunity against coxsackievirus A6 and A10 in mice. Vaccine 36 7095&#x2013;7104. 10.1016/j.vaccine.2018.09.069</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2018.09.069</ArticleId><ArticleId IdType="pubmed">30316529</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z., Dong Z., Wei Q., Carr M. J., Li J., Ding S., et al. (2017b). A neonatal murine model of coxsackievirus a6 infection for evaluation of antiviral and vaccine efficacy. J. Virol. 91:e02450-16. 10.1128/JVI.02450-16</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02450-16</ArticleId><ArticleId IdType="pmc">PMC5391469</ArticleId><ArticleId IdType="pubmed">28250116</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu F. C., Meng F. Y., Li J. X., Li X. L., Mao Q. Y., Tao H., et al. (2013). Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 381 2024&#x2013;2032. 10.1016/S0140-6736(13)61049-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(13)61049-1</ArticleId><ArticleId IdType="pubmed">23726161</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu F., Xu W., Xia J., Liang Z., Liu Y., Zhang X., et al. (2014). Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. N. Engl. J. Med. 370 818&#x2013;828.</Citation><ArticleIdList><ArticleId IdType="pubmed">24571754</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>